医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The Largest Plastic Surgery Information Platform in South Korea Launches ‘UNNI’, a Global K-Medical Information App for Foreigners

2023年12月06日 AM01:30
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Healing Paper, the operator of the largest plastic surgery information platform in South Korea, ‘Gangnam Unni’, announced that it launched ‘UNNI,’ a global K-medical information app for foreigners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205938563/en/

Healing Paper launched the Global K-Medical Information Application “UNNI” for overseas users. (Graphic: Healing Paper)

Healing Paper launched the Global K-Medical Information Application “UNNI” for overseas users. (Graphic: Healing Paper)

Since 2015, Gangnam Unni has been providing Korean users with medical information, including pricing details and over 1.3 million reviews on plastic surgery and dermatology clinics. Currently, 1,800 Korean clinics are registered in Gangnam Unni. Among these, UNNI provides information on clinics that wish to advertise overseas to attract foreigners.

UNNI app provides its service in English. Users can download the app and access the chat-consultations to have a consultation and make an appointment, in 13 languages provided by an automatic translation system, including Thai, Vietnamese, and Chinese. UNNI plans to broaden its language support to include medical information like reviews in the future.

UNNI was launched to resolve the information asymmetry between Korean beauty clinics and foreigners. In the past, foreigners struggled to find accurate pricing information and real reviews on Korean beauty clinics and they had to rely on illegal brokers.

A plastic surgery specialist who partners with Gangnam Unni said, “With the possibility of attracting foreigners through platform advertising, there is no longer a need to pay excessive fees to individual brokers. We anticipate that diverse user reviews will provide foreigners with more opportunities for clinic selections.”

Gangnam Unni successfully expanded to Japan in November 2019, becoming the leading platform in the Japanese market. Gangnam Unni provides the beauty and medical information of Korean and Japanese clinics to Japanese users. The number of Japanese users has doubled compared to December 2022 to reach over 0.7 million users. Over 10% of Gangnam Unni’s total 5.5 million users are now from Japan.

Through this global business expansion, Healing Paper operates three services: Gangnam Unni Korea, Gangnam Unni Japan, and UNNI for other overseas countries. The company plans to focus on technology development, domestic and overseas business operations, and marketing efforts from its Korean headquarters and Japanese branch.

Seung-il Hong, CEO of Healing Paper, said, “With the end of the COVID-19 pandemic, diverse and numerous foreigners are visiting Korean clinics and the K-medical market is becoming globally competitive, bolstered by top-notch medical infrastructure and advanced technology. We will strive to provide trustworthy medical information to international consumers and promote Korean beauty medical services to the best of our ability.’

Learn more about http://unni.global
UNNI app download link for Mobile: https://abr.ge/mbissf

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205938563/en/

CONTACT

Healing Paper

Jo-eun Hwang, Communications manager

joanne@gangnamunni.com

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders